Mon Dec 29 14:50:00 UTC 2025: Here’s a summary of the text, followed by a rewrite as a news article:

Summary:

Several institutional investors, including Brookstone Capital Management, have adjusted their positions in Pfizer Inc. (NYSE:PFE) stock. Brookstone significantly increased its holdings, while others like Brighton Jones LLC also made substantial purchases. Analysts are providing varied ratings for Pfizer, with a consensus of “Hold” and an average price target of $28.06. Pfizer recently reported earnings that exceeded expectations, announced an upcoming dividend payment, and provided its FY 2025 guidance. The company’s fundamentals, including its P/E ratio and dividend yield, are highlighted.

News Article:

Brookstone Capital Boosts Stake in Pfizer as Institutional Investors Weigh In

NEW YORK, NY – Brookstone Capital Management significantly increased its investment in Pfizer Inc. (NYSE:PFE) during the third quarter, according to a recent SEC filing. The firm increased its holdings by 134.1%, bringing its total stake to 269,381 shares, valued at $6.864 million. This move comes amidst varied sentiment from other institutional investors and analysts regarding the pharmaceutical giant.

Brighton Jones LLC dramatically increased its stake in Pfizer by 1,282.4% during the fourth quarter. Other firms, including Revolve Wealth Partners LLC, FORA Capital LLC, Landscape Capital Management L.L.C., and Gerber Kawasaki Wealth & Investment Management, also adjusted their positions, indicating continued active trading in Pfizer shares. Currently, institutional investors and hedge funds hold 68.36% of the company’s stock.

Analyst ratings for Pfizer are mixed. A recent report from MarketBeat.com shows that the company has a consensus “Hold” rating, with an average price target of $28.06. Recent reports from HSBC reaffirmed a “Buy” rating, while Wolfe Research issued an “Underperform” rating.

Pfizer recently reported strong earnings for the last quarter, exceeding expectations with an EPS of $0.87. Revenue, however, slightly missed estimates, coming in at $16.65 billion. The company is also set to pay a quarterly dividend of $0.43 per share on March 6th to shareholders of record as of January 23rd, representing a substantial 6.9% annualized dividend yield.

With a market capitalization of $142.68 billion, Pfizer remains a major player in the biopharmaceutical industry. Investors are closely watching the company’s performance and analyst outlook as it navigates a dynamic market landscape.

Read More